# Guideline 14.2 – Acute Coronary Syndromes: Initial Medical Therapy

## Summary

**To whom does this guideline apply?**

This guideline applies to adults.

**Who is the audience for this guideline?**

This guideline is for use by first responders and health professionals in the prehospital and emergency department setting.

### Summary of Recommendations

The Australian and New Zealand Committee on Resuscitation (ANZCOR) makes the following recommendations:

1. Supplemental oxygen should only be initiated if the patient has hypoxemia, signs of heart failure, or shock [Good Practice Statement].
2. Oxygen saturation monitoring should guide oxygen therapy [Good Practice Statement].
3. Nitrates can be used for symptom relief and resolution of ST depression [Good Practice Statement].
4. Opioids such as morphine or fentanyl can be used as first-line analgesia for ongoing chest discomfort that is unresponsive to nitrates [Good Practice Statement].
5. Aspirin administration is recommended with a loading dose of 300 mg followed by regular dosing at 75 to 150 mg daily [Good Practice Statement].
6. ANZCOR suggests anticoagulation with either subcutaneous enoxaparin, intravenous unfractionated heparin (UFH) or other agents in patients with acute coronary syndrome (ACS) [Good Practice Statement].
7. Switching between agents should be avoided [Good Practice Statement].

.

## 1.0 | Symptomatic Therapy

There are several therapies in patients with Acute Coronary Syndromes (ACS) that provide relief for symptoms.

Supplemental oxygen should be initiated if the patient has hypoxaemia (oxygen saturation ($SpO_2$) < 94% with chronic obstructive pulmonary disease (COPD) or < 88% with known carbon dioxide ($CO_2$) retention), or signs of heart failure or shock. The use of oxygen saturation monitoring is useful in guiding oxygen therapy.[1, 2] Oxygen supplementation does not improve outcomes among patients without hypoxemia,[3] and hyperoxaemia is potentially harmful in uncomplicated myocardial infarction.[4] Supplemental oxygen is not advised to treat breathlessness where target $SpO_2$ is achieved with air. In patients with ACS where peripheral oxygen saturations are unobtainable due to poor tissue perfusion, oxygen should be administered.

Nitrates may also be used for symptom relief and resolution of ST depression, with intravenous nitrate being more effective than sublingual nitrate.[5] However, there are no data to suggest a benefit from nitrates outside of symptom control.[6] It is reasonable to consider the early administration of nitrates in selected patients without contraindications.

Opioids such as morphine or fentanyl are traditionally used as first line analgesia for patients with ongoing symptoms of chest discomfort and titrated to relieve pain. Opioids have, however, been associated with slower uptake and delayed onset of antiplatelet action and further research is required regarding the possibility of harm suggested in some studies.[7-11] Though current recommendations do not prohibit the use of opioids, they should only be used for significant ongoing chest pain unresponsive to nitrates. Trials into non opioid analgesia are ongoing.

In the specific setting of cocaine/stimulant-associated chest pain, lorazepam and nitrates may be useful in the alleviation of chest pain.

In general, non-steroidal anti-inflammatory drugs (excluding aspirin) should not be administered in patients with suspected ACS as they could be harmful.[12]

## 2.0 | Antiplatelet and Anticoagulant Therapy

### 2.1 | Aspirin administration

The early administration of aspirin with a loading dose of 300 mg followed by regular dosing at 75 to 150 mg daily is recommended in people with suspected ACS where contraindications such as true anaphylaxis or bleeding disorder have been excluded.[5, 13] They should be directed to chew the

tablet (which should not be enteric coated).[2] Dispersible aspirin may also be used.

Aspirin has been shown to be similar to thrombolysis in reducing ST-elevation myocardial infarction (STEMI) mortality and provides an additive benefit when administered with thrombolysis (ISIS 2).

There is currently limited evidence to directly support the strategy of dispatcher directed or bystander administration of aspirin, however, it is a reasonable approach if the carer can exclude a history of true anaphylaxis or bleeding disorder.[14]

## 2.2 | Antiplatelet Agents

**Ticagrelor** is a pyrimidine derivative and is effective without the need for biotransformation. It is the preferred drug, in conjunction with aspirin, for ACS. Additionally, it has a quicker offset of action so that recovery of platelet function is faster. It is more effective in decreasing death from vascular causes, myocardial infarction, or stroke in comparison to clopidogrel in ACS (9.8% vs 11.7%, $p<0.001$), though ticagrelor was associated with a higher rate of non-procedure related bleeding. The other adverse effects of ticagrelor include dyspnoea, increased frequency of mostly asymptomatic ventricular pauses, and asymptomatic increases in uric acid. Dosing for ACS includes a 180 mg loading dose followed by a 90 mg twice daily maintenance dose.

**Clopidogrel**: Clopidogrel is a prodrug with variable response and should only be used for ACS when ticagrelor or prasugrel are unavailable or are precluded by an unacceptably high bleeding risk.[5]

**Prasugrel**: Prasugrel is a newer thienopyridine, that produces more rapid and consistent platelet inhibition.[17] Prasugrel is one of the preferred antiplatelet options, in addition to aspirin, for ACS. Prasugrel is administered as a loading dose of 60 mg followed by 10 mg daily maintenance dose. At the time of writing, prasugrel is no longer available for clinical use in Australia or New Zealand, however this may be subject to change.

**Timing:** Among STEMI patients, administration can occur in either the prehospital or in-hospital setting, but there is insufficient evidence to change any existing local practice.[2]

There is insufficient evidence to support the administration of a second antiplatelet agent in non-ST segment myocardial infarction (NSTEMI) prior to angiography.

## 3.0 | Anticoagulants

### 3.1 | Anticoagulants in Non-ST Elevation Acute Coronary Syndrome (NSTEACS)

In people presenting with NSTEACS, anticoagulation with either subcutaneous enoxaparin, or

intravenous unfractionated heparin (UFH) is the preferred treatment strategy.[22] This recommendation includes those managed with an initial conservative approach or a planned invasive approach. The use of bivalirudin remains controversial, with several conflicting trials and meta-analyses and a potential concern of increased stent thrombosis risk.[5, 23-27] With current available evidence, bivalirudin may be considered in selected cases, such as in heparin induced thrombocytopenia (HIT).

## 3.2 | Anticoagulants in STEMI treated with Fibrinolysis

In patients with STEMI in the pre-hospital and emergency department (ED) setting, parenteral anticoagulation should be given until revascularisation.[11] In patients with STEMI managed with fibrinolysis, anticoagulation with either enoxaparin (first dose intravenous (omit if > 74 years) followed by subcutaneous) or intravenous UFH is reasonable. The patient should not be switched from enoxaparin to UFH or vice versa as this has been shown to be associated with an increased bleeding risk.

## 3.3 | Anticoagulants in STEMI treated with PCI

Anticoagulation is recommended in all patients with STEMI, and UFH or enoxaparin are preferred. Pre-hospital administration of UFH is reasonable as part of a coordinated system of care. While there are no randomized data assessing UFH in primary PCI, there is a large body of experience with this agent.[11] Enoxaparin may be considered a safe and effective alternative to UFH in the patient with STEMI undergoing PCI. To avoid increased bleeding risks, patients initially treated with enoxaparin or UFH should not be switched to the other agent.[11, 28] The administration of anticoagulants in patients with suspected STEMI and a planned primary percutaneous coronary intervention (PPCI) can occur in-hospital or in the pre-hospital setting.[2]

Data surrounding bivalirudin are mixed with several trials suggesting bivalirudin may reduce bleeding complications compared to UFH, while others identified an increased rate of stent thrombosis observed in patients treated with bivalirudin in the first 24 hours.[25, 27, 29-33] There are other agents that are used less commonly in the hospital setting such as fondaparinux which may be considered in STEMI in some situations.[35]

## 3.4 | Glycoprotein IIBIIIA inhibitors

Routine use of glycoprotein (GP) IIb/IIIa inhibitors in the pre-hospital setting increases bleeding risk without improving outcomes, and therefore is not recommended.[11, 33, 36]

# 4.0 | Optimal Medical Therapy for Primary and Secondary Prevention

There are several additional medical therapies that have been proposed for ACS patients to reduce myocardial ischaemia and recurrent major cardiovascular events and improve long-term survival. Therapeutic options in the pre-hospital and emergency setting that should be specifically addressed include the routine use of antiarrhythmics, beta blockers, angiotensin converting enzyme (ACE) inhibitors and 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA)-reductase inhibitors.

## 4.1 | Antiarrhythmics

There is no high-level evidence to suggest that the prophylactic use of antiarrhythmics improves outcomes in patients with ACS, and negative effects on early mortality have been described.[37, 38] Serious arrhythmias such as ventricular fibrillation (VF) and ventricular tachycardia (VT) may occur in ACS and should be treated according to advanced life support guidelines, but the prophylactic use of antiarrhythmic agents is not recommended.[11]

## 4.2 | Beta Blockers

Beta-blockers lower heart rate and myocardial contractility, thereby reducing myocardial oxygen consumption, which is useful in the setting of ischemia. Early administration within 24 hours of admission is reasonable provided there are no contraindications to treatment. However, in patients at risk of cardiogenic shock early initiation of beta-blockers pre-hospital or in ED is associated with increased risk of death or shock compared to patients treated later but within 24 hours. Similarly, routine use of intravenous (IV) beta blockers in the pre-hospital setting or during initial assessment in the ED is not supported by the available evidence.[40] Of note, beta-blockers should not be given in patients with probable coronary vasospasm or cocaine use due to the risk of alpha-mediated vasoconstriction without beta-mediated vasodilation.

## About this Guideline

| Search date/s | This review was completed in October 2023 |
|---|---|

| Questions/PICOs: | This guideline has been developed from the previous ANZCOR guideline 2016 and questions included in the ILCOR 2015 and 2022 CoSTR |
|---|---|
| Method: | Literature review of the most recent acute coronary syndrome and related guidelines from the Australian Heart Foundation / Cardiac Society of Australia and NZ (2016), the European Society of Cardiology (2020) in addition to related ILCOR reviews to produce a locally relevant document. |
| Main Changes: | |
| Principal reviewers: | Dion Stub, Peter Leman, Tony Scott, George Lukas, Luke Dawson |
| Other consultation: | N/A |
| Worksheet: | N/A |
| Approved: | December 2024 |
| Guideline superseded: | Guidelines 14.0, 14.1, 14.1.2, 14.2, 14.3 |

## 4.3 | Other drugs

There is little data to support the routine use of calcium channel blockers in the pre hospital and emergency setting. Reductions in mortality have not been reported in this setting[58].

## References

1. Wilson AT, Channer KS. Hypoxaemia and supplemental oxygen therapy in the first 24 hours after myocardial infarction: The role of pulse oximetry. *J R Coll* Ph*ysicians Lond*. 1997;31:657-661
2. Nikolaou NI, Welsford M, Beygui F, Bossaert L, Ghaemmaghami C, Nonogi H, et al. Part 5: Acute coronary syndromes: 2015 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. *Resuscitation*. 2015;95:e121-146
3. Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen therapy in suspected acute myocardial infarction. *N Engl J Med*. 2017;377:1240-1249
4. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air versus oxygen in st-segment-elevation myocardial infarction. *Circulation*. 2015;131:2143-2150
5. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines

for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2020;29:29

6. Isis-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Isis-4 (fourth international study of infarct survival) collaborative group. 1995

7. McEvoy JW, Ibrahim K, Kickler TS, Clarke WA, Hasan RK, Czarny MJ, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: The pacify randomized clinical trial (platelet aggregation with ticagrelor inhibition and fentanyl). *Circulation*. 2018;137:307-309

8. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the crusade quality improvement initiative. *Am Heart J*. 2005;149:1043-1049

9. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: The randomized, double-blind, placebo-controlled impression trial. *Eur Heart J*. 2016;37:245-252

10. Hobl EL, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, Sunder-Plassmann R, et al. Morphine decreases clopidogrel concentrations and effects: A randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol*. 2014;63:630-635

11. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018;39:119-177

12. Schjerning Olsen A-M, Gislason GH, McGettigan P, Fosbøl E, Sørensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. *Jama*. 2015;313:805-814

13. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 esc focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic Surgery (EACTS). *Eur Heart J*. 2018;39:213-260

14. Freimark D, Matetzky S, Leor J, Boyko V, Barbash IM, Behar S, et al. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. *Am J Cardiol*. 2002;89:381-385

15. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045-1057

16. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001-2015

17. Syed FA, Bett JH, Walters DL. Anti-platelet therapy for acute coronary syndrome: A review of currently available agents and what the future holds. *Cardiovasc Hematol Disord Drug Targets*. 2011;11:79-86

18. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. *N Engl J Med*.

2013;369:999-1010

19. Redfors B, Dworeck C, Haraldsson I, Angeras O, Odenstedt J, Ioanes D, et al. Pretreatment with p2y12 receptor antagonists in ST-elevation myocardial infarction: A report from the swedish coronary angiography and angioplasty registry. *Eur Heart J*. 2019;40:1202-1210

20. Montone RA, Hoole SP, West NE. Prehospital ticagrelor in ST-segment elevation myocardial infarction. *N Engl J Med*. 2014;371:2338-2339

21. Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. *N Engl J Med*. 2014;371:1016-1027

22. Eikelboom JW, Anand Ss Fau - Malmberg K, Malmberg K Fau - Weitz JI, Weitz Ji Fau - Ginsberg JS, Ginsberg Js Fau - Yusuf S, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet 2000;355:1936–1942.

23. Steg PG, van 't Hof A, Fau - Hamm CW, Clemmensen P, Clemmensen P, Lapostolle F, Coste P, Coste P Fau - Ten Berg J, et al. Bivalirudin started during emergency transport for primary PCI. *N Engl J Med***2013;369:2207-2217**

24. Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, et al. Prasugrel plus bivalirudin vs. Clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. *Eur Heart J*, 2014;35:2285–2294

25. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med*. 2008;358:2218-2230

26. Silvain J, Beygui F, Barthelemy O, Pollack C, Jr., Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: Systematic review and meta-analysis. *Bmj*. 2012;344:e553

27. Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, et al. Prasugrel plus bivalirudin vs. Clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. *Eur Heart J*. 2014;35:2285-2294

28. Zeymer U, Gitt A, Zahn R, Junger C, Bauer T, Heer T, et al. Efficacy and safety of enoxaparin in combination with and without gp iib/iiia inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *EuroIntervention*. 2009;4:524-528

29. Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al. Bivalirudin started during emergency transport for primary PCI. *N Engl J Med*. 2013;369:2207-2217

30. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (heat-PPCI): An open-label, single centre, randomised controlled trial. *Lancet*. 2014;384:1849-1858

31. Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: The bright randomized clinical trial. *Jama*. 2015;313:1336-1346

32. Zeymer U, van 't Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, et al. Bivalirudin is superior to heparins alone with bailout gp iib/iiia inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: A pre-specified analysis from the euromax trial. *Eur Heart J*. 2014;35:2460-2467

33. Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, Stone GW. Bivalirudin versus heparin with or without glycoprotein iib/iiia inhibitors in patients with stemi

undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. *Europ Heart J Acute Cardiovasc Care*. 2016;5:253-262

34. Valgimigli M, Frigoli E Fau - Leonardi S, Leonardi S Fau - Rothenbühler M, Rothenbühler M Fau - Gagnor A, Gagnor A Fau - Calabrò P, Calabrò P Fau - Garducci S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. 2015

35. The O-TG. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction the oasis-6 randomized trial. *JAMA*. 2006;295:1519-1530

36. Ten Berg JM, Van 't Hof AW, Dill T, Heestermans T, Van Werkum JW, Mosterd A, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. *J Am Coll Cardiol*. 2010;55:2446-2455

37. Wyman MG, Wyman RM, Cannom DS, Criley JM. Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine. *Am J Cardiol*. 2004;94:545-551

38. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. *Crit Care Med*. 2011;39:78-83

39. Pickering JW, Young JM, George PM, Watson AS, Aldous SJ, Troughton RW, et al. Validity of a novel point-of-care troponin assay for single-test rule-out of acute myocardial infarction. *JAMA Cardiol*. 2018;3:1108-1112

40. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. *Lancet*. 2005;366:1622-1632

41. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ace-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Ace-inhibitor myocardial infarction collaborative group. *Lancet*. 2000;355:1575-1581

42. Heart Outcomes Prevention Evaluation Study I, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342:145-153

43. Patel A, Group AC, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the advance trial): A randomised controlled trial. *Lancet*. 2007;370:829-840

44. Patti G, Cannon Cp Fau - Murphy SA, Murphy Sa Fau - Mega S, Mega S Fau - Pasceri V, Pasceri V Fau - Briguori C, Briguori C Fau - Colombo A, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: A collaborative patient-level meta-analysis of 13 randomized studies. 2011

45. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387-2397

46. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. *BMJ (Clinical research ed.)*. 1989;299:1187-1192

47. Anonymous. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish verapamil infarction trial ii--davit ii). *Am J Cardiol*. 1990;66:779-785

# Abbreviations

| Abbreviation | Meaning/Phrase |
|---|---|
| ACE | Angiotensin converting enzyme |
| ACS | Acute coronary syndrome |
| ANZCOR | Australian and New Zealand Committee on Resuscitation |
| ARC | Australian Resuscitation Council |
| $CO_2$ | Carbondioxide |
| COPD | Chronic obstructive pulmonary disease |
| ED | Emergency department |
| HIT | Heparin induced thrombocytopenia |
| HMG CoA | 3-hydroxy-3-methyl-glutaryl-coenzyme A |
| IV | Intravenous |
| MI | Myocardial infarction |
| NSTEACS | Non-ST elevation acute coronary syndrome |
| NSTEMI | Non-ST elevation myocardial infarction |
| PCI | Percutaneous coronary intervention |
| PPCI | Primary percutaneous coronary intervention |
| $SpO_2$ | Oxygen saturation |
| STEMI | ST elevation myocardial infarction |
| UFH | Unfractionated heparin |
| VF | Ventricular fibrillation |
| VT | Ventricular tachycardia |

# Referencing this guideline

When citing the ANZCOR Guidelines we recommend:

*ANZCOR, 2026, Guideline 14.2 – Acute Coronary Syndromes: Initial Medical Therapy, accessed 4 May 2026,*

[https://www.anzcor.org/home/acute-coronary-syndromes/guideline-14-2-acute-coronary-syndromes-initial-medical-therapy](https://www.anzcor.org/home/acute-coronary-syndromes/guideline-14-2-acute-coronary-syndromes-initial-medical-therapy)